Mirae Asset Global Investments Co. Ltd. Buys 53,178 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Mirae Asset Global Investments Co. Ltd. grew its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOMFree Report) by 16.4% during the 1st quarter, Holdings Channel reports. The firm owned 377,749 shares of the company’s stock after purchasing an additional 53,178 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Global X Genomics & Biotechnology ETF were worth $4,431,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in GNOM. Raymond James Financial Services Advisors Inc. boosted its position in Global X Genomics & Biotechnology ETF by 4.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 263,328 shares of the company’s stock valued at $2,997,000 after buying an additional 12,342 shares in the last quarter. McGuire Investment Group LLC boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 6.7% in the 1st quarter. McGuire Investment Group LLC now owns 58,651 shares of the company’s stock worth $667,000 after acquiring an additional 3,696 shares in the last quarter. Corrado Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter worth approximately $638,000. Prosperity Wealth Management Inc. acquired a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter valued at $544,000. Finally, Stratos Wealth Partners LTD. raised its position in Global X Genomics & Biotechnology ETF by 15.4% in the 4th quarter. Stratos Wealth Partners LTD. now owns 45,014 shares of the company’s stock valued at $520,000 after purchasing an additional 6,013 shares during the last quarter. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

Global X Genomics & Biotechnology ETF stock opened at $10.62 on Thursday. Global X Genomics & Biotechnology ETF has a 52 week low of $8.63 and a 52 week high of $12.58. The firm has a market cap of $96.85 million, a P/E ratio of -4.54 and a beta of 1.03. The business’s fifty day moving average is $10.49 and its two-hundred day moving average is $10.92.

Global X Genomics & Biotechnology ETF Company Profile

(Free Report)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.

See Also

Want to see what other hedge funds are holding GNOM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global X Genomics & Biotechnology ETF (NASDAQ:GNOMFree Report).

Institutional Ownership by Quarter for Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.